

A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

NCT06932523

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Shanghai Institute Of Biological Products
Enrollment	645 participants

Key Eligibility Criteria

Inclusion (7)

- Age ≥ 40 years old on the day of enrollment, gender not limited.
 - Can provide legal proof of identity.
 - Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment.
 - Be able to participate in all planned follow-up visits and comply with all trial procedures.
 - On the day of enrollment, the body temperature was less than 37.3 (axillary temperature).
- ... and 2 more (see full listing online)

Exclusion (22)

- Individuals with a history of herpes zoster in the past.
 - Individuals with a history of vaccination against chickenpox or shingles.
 - Individuals who have had close contact with patients with chickenpox or shingles in the past 2 years.
 - Women of childbearing age who have a positive urine pregnancy test, are breastfeeding, pregnant, or plan to become pregnant within 6 months after the start of the test and the full exemption period.
 - Individuals who are allergic to any component of the vaccine or have a history of other severe allergies.
- ... and 17 more (see full listing online)

Locations (1 total)

Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China